In a Thai retrospective study, advanced cholangiocarcinoma patients receiving medical cannabis survived a median of 5.7 months versus 0.8 months with standard palliative care — a dramatic difference that warrants cautious interpretation.
Read this if you're interested in cannabis and cancer outcomes — this study shows a striking survival difference, but understanding why the retrospective design limits conclusions is just as important as the numbers.
What the researchers found
Cholangiocarcinoma (bile duct cancer) is devastating in Northeast Thailand, where incidence is among the highest in the world due to endemic liver fluke infections. Most patients are diagnosed at advanced stages with poor prognoses and very short survival times.
This retrospective study compared 491 newly diagnosed advanced cholangiocarcinoma patients across six hospitals: 404 received standard palliative pain management and 87 received medicinal cannabis treatment (Thailand was the first Southeast Asian country to legalize medical cannabis). The results were dramatic.
Median survival for the standard treatment group was 0.83 months (about 25 days). For the cannabis treatment group, median survival was 5.66 months — nearly seven times longer. The mortality rate was 48.35 per 100 person-months in the standard group versus 10.9 per 100 person-months in the cannabis group.
These numbers are eye-catching, but they demand careful interpretation. This was a retrospective study, not a randomized trial. Patients who received cannabis treatment may have been systematically different from those who didn't — perhaps healthier at baseline, more engaged with their care, or diagnosed earlier despite being classified as 'advanced.' Selection bias is a major concern. The survival difference is also far larger than what's been seen in any cannabis-cancer study, which raises questions about confounding factors rather than confirming a direct cannabis anti-tumor effect.
Why it matters
Cancer survival claims for cannabis are among the most emotionally charged topics in cannabis research. This study shows a real survival difference in real patients, but the retrospective design means we can't conclude cannabis caused the difference. What this study does well is document that medical cannabis can be integrated into palliative cancer care in a Southeast Asian healthcare setting, and that the survival difference is large enough to justify the randomized controlled trials needed to establish causation.
The numbers in context
491 patients total: 404 standard care, 87 cannabis treatment. Standard care median survival: 0.83 months (95% CI: 0.71–0.95). Cannabis group median survival: 5.66 months. Standard care mortality rate: 48.35/100 person-months. Cannabis group mortality rate: 10.9/100 person-months. Total follow-up: 790 person-months (standard) and 476 person-months (cannabis).
How the study worked
Retrospective cohort study comparing survival among 491 newly diagnosed advanced cholangiocarcinoma patients from six hospitals in Northeast Thailand (September 2019–June 2021). The cannabis group (87 patients) received medical cannabis treatment; the standard group (404 patients) received conventional palliative pain management. Survival was calculated using Kaplan-Meier methods, and prognostic factors were analyzed using Cox regression.
Who was studied
N=491 adults aged 40-80, 50% male, advanced cholangiocarcinoma patients in Northeastern Thailand.
What this study cannot tell us
Retrospective design with no randomization — selection bias is the primary concern. Patients who sought out cannabis treatment may have been systematically healthier, more motivated, or had better access to healthcare. The standard care group's median survival of 0.83 months is extremely short, suggesting these patients may have been at a more advanced disease stage. No blinding was possible. Cannabis dosing and formulations were not standardized. Cultural and regional factors in Thailand may limit generalizability to other populations.
How to read the evidence
This is a retrospective cohort study with a large sample but no randomization. The dramatic survival difference is attention-grabbing but highly susceptible to selection bias, making it hypothesis-generating rather than conclusive.
When this study was published
Published in 2022, based on patients treated 2019–2021 during the early phase of Thailand's medical cannabis program.
The bigger picture
This study is important to contextualize carefully. The cannabis-and-cancer research space is full of in vitro studies showing cannabinoids can kill cancer cells in a dish, but very few human studies showing meaningful clinical outcomes. This retrospective study shows a provocative survival signal, but it's the kind of finding that generates hypotheses rather than proving them. Randomized trials are essential before drawing any treatment conclusions.
Replication
Not stated in abstract.
Funding
Not reported in abstract.
Conflicts of interest
Not reported in abstract.
Questions still open
- Would a randomized controlled trial replicate this dramatic survival difference? Were the two groups truly comparable in disease stage and baseline health? Is the survival benefit driven by cannabis anti-tumor effects, better symptom management (leading to better nutrition and function), or selection bias? Can these findings be generalized beyond the specific epidemiology of cholangiocarcinoma in Thailand?
Read the original research
Survival rate of patients with combined hepatocellular cholangiocarcinoma receiving medical cannabis treatment: A retrospective, cohort comparative study.
F1000Research, 11, 1212
F1000Research is a reputable open-access journal known for publishing high-quality research across various fields.
Citation
Phansila, Narisara; Pansila, Paopong; Wongkongdech, Adisorn; Turnbull, Niruwan; Azam, Mahalul; Wongkongdech, Ranee. (2022). Survival rate of patients with combined hepatocellular cholangiocarcinoma receiving medical cannabis treatment: A retrospective, cohort comparative study.. F1000Research, 11, 1212. https://doi.org/10.12688/f1000research.123250.3
Explore the wider topic
- CBD Oil Quality Guide: How to Avoid Snake Oil
- Anxiety After Quitting Weed: When to Consider Medication
- Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
- Cannabis for Chronic Pain: What the Research Actually Supports
- Cannabis and Epilepsy: The Epidiolex Story and What It Means
- Does CBD Actually Work for Anxiety? What the Evidence Shows
- Does CBD Help with Weed Withdrawal? What Studies Show
- CBD vs THC: The Differences That Actually Matter
- The Proven Medical Benefits of Cannabis: What Research Supports
- Quitting Weed Before Surgery
- Weed and Medications: What Changes When You Quit
- Quitting Weed During Pregnancy: What You Need to Know
- Quitting Weed While Pregnant: What You Need to Know
- Cannabis and Older Adults: Risks Seniors Should Know
- Cannabis and Breastfeeding: THC in Breast Milk